According to data from the market intelligence miners at EvaluatePharma, worldwide sales of generic drugs in 2014 were $74.2 billion, up 7% for the year. Of that, the top 20 generics producers collected $61.7 billion, 83.1% of the take.
Mylan has swept aside one of the legal hurdles set up by Perrigo, which has been fighting on two continents to try to derail Mylan's takeover of the generics competitor.
India is not part of the recently negotiated Trans-Pacific Partnership trade deal, but that doesn't mean the TPP won't still have a trade impact on its drug industry. As some industry veterans see it, the free-trade agreement spells bad news for the $15 billion drug industry that India has built by being a go-to country for cheap generic drugs.
Turing Pharmaceuticals faces a new adversary: New York's attorney general. AG Eric Schneiderman's office has launched an antitrust investigation into Turing, the drugmaker whose 5000% price hike put the pharma industry's pricing policies under a microscope.
Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.
Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.
Big Pharma is having a dealmaking fiesta in Mexico, with companies such as Sanofi, Pfizer and Teva Pharmaceutical Industries considering buying local generic drugmaker Representaciones e Investigaciones Medicas, also known as Rimsa, to beef up business south of the border.
After scrambling to convert Namenda patients over to a newer, longer-lasting version of the med, Allergan certainly doesn't want generic competition to the updated version. And for now, it's dodged a bullet, by striking an accord with Amneal to keep its copy off the market for more than four years.
Belgium's UCB has had a tough time unloading its U.S. generic drug business, calling off a sale last year amid regulatory pushback over one of the unit's products. Now the company is closing one chapter and moving on to the next, selling the business to Lannett for $1.23 billion to lighten its load and refocus on high-growth areas.
Teva's $40.5 billion deal for Allergan's generics business, announced last week, was just the latest to hit a rapidly consolidating generics industry. And while the M&A bug is sweeping through the wider pharma industry, in generics, there's an added factor pushing copycats to join hands.